<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2026-02-02</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2026-02-02</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>74</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>1</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
Xeniumç©ºé—´è½¬å½•ç»„æŠ€æœ¯é¦–æ¬¡åº”ç”¨äºæ—©æœŸèƒšèƒå‘è‚²åŠè¾èˆå°¾éƒ¨å†ç”Ÿç ”ç©¶ã€‚ microRNA-25é€šè¿‡Syndecan3è°ƒæ§å…ˆå¤©å’Œä½“æ¶²å…ç–«ï¼Œæ­ç¤ºäº†å…¶åœ¨å…ç–«æ£€æŸ¥ç‚¹æ²»ç–—è€è¯ä¸­çš„å…³é”®ä½œç”¨ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç™Œç—‡ä¾µè¢­ä¸å…ç–«æµ¸æ¶¦ï¼šCSN3åœ¨èƒƒç™Œä¸­ä¿ƒè¿›ä¾µè¢­å¹¶å½±å“å…ç–«æµ¸æ¶¦ã€‚<br />
- å…ç–«æ²»ç–—è€è¯æœºåˆ¶ï¼šmicroRNA-25åœ¨å°é¼ æ¨¡å‹ä¸­é€šè¿‡Syndecan3ä»‹å¯¼å…ç–«æ£€æŸ¥ç‚¹æ²»ç–—è€è¯ã€‚<br />
- å‘è‚²ç”Ÿç‰©å­¦ä¸å†ç”Ÿï¼šåˆ©ç”¨XeniumæŠ€æœ¯è§£æè¾èˆèƒšèƒå’Œå°¾éƒ¨å†ç”Ÿè¿‡ç¨‹çš„ç»†èƒå¼‚è´¨æ€§ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- Xeniumç©ºé—´è½¬å½•ç»„æŠ€æœ¯ï¼šå®ç°é«˜åˆ†è¾¨ç‡çš„ç©ºé—´åŸºå› è¡¨è¾¾åˆ†æã€‚<br />
- æ•´åˆå¤šç»„å­¦æ–¹æ³•ï¼šç»“åˆRNA-seqã€ATAC-seqç­‰æŠ€æœ¯æ·±å…¥è§£æåˆ†å­æœºåˆ¶ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (74æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>GSE317661 CSN3ä¿ƒè¿›èƒƒç™Œä¾µè¢­ï¼Œå¹¶é€šè¿‡æ¿€æ´»NOD/TLRé€šè·¯ä¸å…ç–«æµ¸æ¶¦ç›¸å…³</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€immuneã€TLR<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Gang Wang ; Dalai Xu ; Lei Qiu ; Feng Lu ; Yongchang MiaoSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWe found that CSN3 is highly expressed in gastric cancer and is associated with advanced tumor stage, lymph node metastasis, and poor prognosis. Functional assays showed that CSN3 promotes proliferation and migration while inhibiting apoptosis in GC cells. RNA-sequencing revealed that CSN3 overexpression predominantly activates innate immuneâ€“related pathways, particularly the NOD-like receptor and Toll-like receptor signaling pathways, suggesting a role for CSN3 in inflammatory and immune remodeling of the tumor microenvironment. Consistently, CSN3 expression was positively correlated with B-cell and CD8âº T-cell infiltration, indicating that CSN3-driven transcriptional programs may link tumor aggressiveness with immune microenvironment alterations.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317661" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>GSE313338 Xenium ç©ºé—´è½¬å½•ç»„å­¦ç ”ç©¶ 28 æœŸèƒšèƒå’Œå†ç”Ÿ 3 å˜ç±³å¢¨è¥¿å“¥é’å£èˆå°¾å·´ï¼ˆ3ã€7ã€10ã€14 å¤©åï¼‰ï¼ŒåŒ…æ‹¬æˆç†Ÿçš„æœªæˆªå°¾å°¾å·´</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šspatialã€spatial transcriptomicsã€transcriptomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Vijayishwer S Jamwal ; Riley Grindle ; Ryan P Seam ; Fred Kolling ; Prayag Murawala ; Joel GraberSeries Type : OtherOrganism : Ambystoma mexicanum100 genes were selected, including cell-specific markers, transcription factors and signalling molecules, to understand tail patterning and gene oscillations in the embryo and in comparison to the tail.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313338" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>GSE313080 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Non-coding RNA profiling by high throughput sequencing ; Expression profiling by high throughput sequencingOrganism : Mus musculusThis SuperSeries is composed of the SubSeries listed below.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313080" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>GSE313005 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ [single_clone_RNA_seq_B16]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhouting Zhu ; Zhaoyang Jia ; Tariq M RanaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune Checkpoint Therapy (ICT) has demonstrated durable responses and long-lasting immunologic memory in cancer treatment. However, overcoming primary and acquired resistance remains a major challenge. Here, we show that CRISPR-Cas9-mediated deletion of miRNA-25 (miR-25) sensitizes tumors to ICT across three syngeneic mouse tumor models. Single-cell RNA sequencing (scRNA-seq) of the tumor microenvironment (TME) revealed that miR-25 deficiency induces innate immunity by upregulating major histocompatibility complex class II (MHC II) in antigen-presenting M1-like macrophages and enhances the classical complement cascade in cancer-associated fibroblasts (CAFs) to drive a humoral immune response. The complement activation polarizes CAFs from myofibroblastic CAFs (myCAFs) toward inflammatory CAFs (iCAFs) while simultaneously reduces immune-suppressive interactions between CAFs and tumor associated macrophages (TAMs). This shift results in a reduced macrophage population and fosters a pro-inflammatory, anti-tumor TME. Syndecan-3 (Sdc3), a membrane proteoglycan expressed in tumors, is repressed by miR-25 through miRISC (microRNA induced silencing complex) upon IFN-Î³ exposure. Using an adenine base editor (ABE8e) to mutate the miR-25 binding site in the 3â€™ untranslated region (3â€™ UTR) of Sdc3 effectively overcomes the resistance. The repression of SDC3 by miR-25 is further validated in five human cancer cell lines upon IFN-Î³ exposure but remains unaffected in non-cancerous cells. These findings identify miR-25 as a key driver of initial resistance through the repression of SDC3 and demonstrate that miR-25 deletion or stabilization of SDC3 could transform immune resistant "cold" tumors into immune responsive "hot" tumors, offering therapeutic avenues to enhance cancer immunotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313005" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>GSE313004 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ [single_cell_RNA_seq_MC38]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhouting Zhu ; Zhaoyang Jia ; Tariq M RanaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune Checkpoint Therapy (ICT) has demonstrated durable responses and long-lasting immunologic memory in cancer treatment. However, overcoming primary and acquired resistance remains a major challenge. Here, we show that CRISPR-Cas9-mediated deletion of miRNA-25 (miR-25) sensitizes tumors to ICT across three syngeneic mouse tumor models. Single-cell RNA sequencing (scRNA-seq) of the tumor microenvironment (TME) revealed that miR-25 deficiency induces innate immunity by upregulating major histocompatibility complex class II (MHC II) in antigen-presenting M1-like macrophages and enhances the classical complement cascade in cancer-associated fibroblasts (CAFs) to drive a humoral immune response. The complement activation polarizes CAFs from myofibroblastic CAFs (myCAFs) toward inflammatory CAFs (iCAFs) while simultaneously reduces immune-suppressive interactions between CAFs and tumor associated macrophages (TAMs). This shift results in a reduced macrophage population and fosters a pro-inflammatory, anti-tumor TME. Syndecan-3 (Sdc3), a membrane proteoglycan expressed in tumors, is repressed by miR-25 through miRISC (microRNA induced silencing complex) upon IFN-Î³ exposure. Using an adenine base editor (ABE8e) to mutate the miR-25 binding site in the 3â€™ untranslated region (3â€™ UTR) of Sdc3 effectively overcomes the resistance. The repression of SDC3 by miR-25 is further validated in five human cancer cell lines upon IFN-Î³ exposure but remains unaffected in non-cancerous cells. These findings identify miR-25 as a key driver of initial resistance through the repression of SDC3 and demonstrate that miR-25 deletion or stabilization of SDC3 could transform immune resistant "cold" tumors into immune responsive "hot" tumors, offering therapeutic avenues to enhance cancer immunotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313004" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>GSE313003 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ [In_vitro_RNA_seq_B16]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhouting Zhu ; Zhaoyang Jia ; Tariq M RanaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune Checkpoint Therapy (ICT) has demonstrated durable responses and long-lasting immunologic memory in cancer treatment. However, overcoming primary and acquired resistance remains a major challenge. Here, we show that CRISPR-Cas9-mediated deletion of miRNA-25 (miR-25) sensitizes tumors to ICT across three syngeneic mouse tumor models. Single-cell RNA sequencing (scRNA-seq) of the tumor microenvironment (TME) revealed that miR-25 deficiency induces innate immunity by upregulating major histocompatibility complex class II (MHC II) in antigen-presenting M1-like macrophages and enhances the classical complement cascade in cancer-associated fibroblasts (CAFs) to drive a humoral immune response. The complement activation polarizes CAFs from myofibroblastic CAFs (myCAFs) toward inflammatory CAFs (iCAFs) while simultaneously reduces immune-suppressive interactions between CAFs and tumor associated macrophages (TAMs). This shift results in a reduced macrophage population and fosters a pro-inflammatory, anti-tumor TME. Syndecan-3 (Sdc3), a membrane proteoglycan expressed in tumors, is repressed by miR-25 through miRISC (microRNA induced silencing complex) upon IFN-Î³ exposure. Using an adenine base editor (ABE8e) to mutate the miR-25 binding site in the 3â€™ untranslated region (3â€™ UTR) of Sdc3 effectively overcomes the resistance. The repression of SDC3 by miR-25 is further validated in five human cancer cell lines upon IFN-Î³ exposure but remains unaffected in non-cancerous cells. These findings identify miR-25 as a key driver of initial resistance through the repression of SDC3 and demonstrate that miR-25 deletion or stabilization of SDC3 could transform immune resistant "cold" tumors into immune responsive "hot" tumors, offering therapeutic avenues to enhance cancer immunotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313003" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>GSE313002 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ [Bulk_tumor_RNA_seq_B16]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhouting Zhu ; Zhaoyang Jia ; Lingling Wang ; Hui Hui ; Tariq M RanaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusImmune Checkpoint Therapy (ICT) has demonstrated durable responses and long-lasting immunologic memory in cancer treatment. However, overcoming primary and acquired resistance remains a major challenge. Here, we show that CRISPR-Cas9-mediated deletion of miRNA-25 (miR-25) sensitizes tumors to ICT across three syngeneic mouse tumor models. Single-cell RNA sequencing (scRNA-seq) of the tumor microenvironment (TME) revealed that miR-25 deficiency induces innate immunity by upregulating major histocompatibility complex class II (MHC II) in antigen-presenting M1-like macrophages and enhances the classical complement cascade in cancer-associated fibroblasts (CAFs) to drive a humoral immune response. The complement activation polarizes CAFs from myofibroblastic CAFs (myCAFs) toward inflammatory CAFs (iCAFs) while simultaneously reduces immune-suppressive interactions between CAFs and tumor associated macrophages (TAMs). This shift results in a reduced macrophage population and fosters a pro-inflammatory, anti-tumor TME. Syndecan-3 (Sdc3), a membrane proteoglycan expressed in tumors, is repressed by miR-25 through miRISC (microRNA induced silencing complex) upon IFN-Î³ exposure. Using an adenine base editor (ABE8e) to mutate the miR-25 binding site in the 3â€™ untranslated region (3â€™ UTR) of Sdc3 effectively overcomes the resistance. The repression of SDC3 by miR-25 is further validated in five human cancer cell lines upon IFN-Î³ exposure but remains unaffected in non-cancerous cells. These findings identify miR-25 as a key driver of initial resistance through the repression of SDC3 and demonstrate that miR-25 deletion or stabilization of SDC3 could transform immune resistant "cold" tumors into immune responsive "hot" tumors, offering therapeutic avenues to enhance cancer immunotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313002" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>GSE313001 microRNA-25 é€šè¿‡ Syndecan3 æŠ‘åˆ¶å…ˆå¤©æ€§å’Œä½“æ¶²å…ç–«ï¼Œä»è€Œé©±åŠ¨å¯¹å…ç–«æ£€æŸ¥ç‚¹ç–—æ³•çš„åˆå§‹è€è¯æ€§ [small_RNA_seq_B16]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šimmuneã€immunityã€resistance<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Zhouting Zhu ; Zhaoyang Jia ; Gulshanbir Baidwan ; Hui Hui ; Tariq M RanaSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Mus musculusImmune Checkpoint Therapy (ICT) has demonstrated durable responses and long-lasting immunologic memory in cancer treatment. However, overcoming primary and acquired resistance remains a major challenge. Here, we show that CRISPR-Cas9-mediated deletion of miRNA-25 (miR-25) sensitizes tumors to ICT across three syngeneic mouse tumor models. Single-cell RNA sequencing (scRNA-seq) of the tumor microenvironment (TME) revealed that miR-25 deficiency induces innate immunity by upregulating major histocompatibility complex class II (MHC II) in antigen-presenting M1-like macrophages and enhances the classical complement cascade in cancer-associated fibroblasts (CAFs) to drive a humoral immune response. The complement activation polarizes CAFs from myofibroblastic CAFs (myCAFs) toward inflammatory CAFs (iCAFs) while simultaneously reduces immune-suppressive interactions between CAFs and tumor associated macrophages (TAMs). This shift results in a reduced macrophage population and fosters a pro-inflammatory, anti-tumor TME. Syndecan-3 (Sdc3), a membrane proteoglycan expressed in tumors, is repressed by miR-25 through miRISC (microRNA induced silencing complex) upon IFN-Î³ exposure. Using an adenine base editor (ABE8e) to mutate the miR-25 binding site in the 3â€™ untranslated region (3â€™ UTR) of Sdc3 effectively overcomes the resistance. The repression of SDC3 by miR-25 is further validated in five human cancer cell lines upon IFN-Î³ exposure but remains unaffected in non-cancerous cells. These findings identify miR-25 as a key driver of initial resistance through the repression of SDC3 and demonstrate that miR-25 deletion or stabilization of SDC3 could transform immune resistant "cold" tumors into immune responsive "hot" tumors, offering therapeutic avenues to enhance cancer immunotherapy.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313001" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>GSE309890 æŠ—æŠ‘éƒè¯èˆæ›²æ—é€šè¿‡åº”æ¿€é©±åŠ¨çš„ç£·é…¸æˆŠç³–é€”å¾„é‡ç¼–ç¨‹å¯¼è‡´è€è¯æ€§äº§ç”Ÿï¼štktA ä½¿ä»£è°¢å›æ»š</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolicã€resistanceã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Yueting Cui ; Shiyuan Xue ; Jianhua Guo ; Chengdong ZhangSeries Type : Expression profiling by high throughput sequencingOrganism : Escherichia coli str. K-12 substr. MG1655Selective serotonin reuptake inhibitors (SSRIs) may accelerate antibiotic resistance, but the metabolic changes behind this processâ€”and how to restore susceptibilityâ€”are still not well understood. We demonstrated that sertraline led to a biased resistance profile in Escherichia coli, characterized by early accumulation of mutations targeting rifampicin and ciprofloxacin. These genetic alterations were linked to a compensatory respiratory mechanism dependent on Complex I, leading to reduced nicotinamide adenine dinucleotide and superoxide/hydrogen peroxide buildup. They also caused a rapid shift of glucose from glycolysis to the pentose-phosphate pathway (PPP) to produce reduced nicotinamide adenine dinucleotide phosphate during oxidative stress, similar to paraquat-like redox stress. Inhibiting the non-oxidative PPP, especially transketolase A (tktA), eliminated the sertraline-primed advantage and brought back antibiotic susceptibility, decreasing survival by approximately 10,000 times during antibiotic challenge, even with rpoBC and gyrAB mutations fixed. These findings uncover an electron transfer chain/PPPâ€“coupled redox module as the hidden driver behind sertraline-induced resistance, highlighting mutation-agnostic ways to restore bacterial sensitivity. By reframing SSRI-induced resistance as a modifiable metabolic trait, we provide a basis for using metabolic adjuvants to shield the millions of SSRI users from the unintended risk of antibiotic resistanceâ€”transforming a pharmacological challenge into a manageable, reversible target<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309890" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>GSE266852 åˆ©ç”¨å•ç»†èƒè½¬å½•ç»„æµ‹åºåˆ†ææ¯”è¾ƒå¥åº·å¯¹ç…§è€…ã€ç±»é£æ¹¿æ€§å…³èŠ‚ç‚æ‚£è€…å’Œç‹¼ç–®æ‚£è€…è¡€æ¶² PBMC ä¸­çš„å·®å¼‚åŸºå› è¡¨è¾¾ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencingã€single-cellã€transcriptome<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensSingle-cell transcriptome sequencing was used to detect and compare differentially expressed genes in PBMCs from healthy controls in patients with rheumatoid arthritis, systemic lupus erythematosus patients.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE266852" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 64 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>RNA-seq</td>
<td>11</td>
</tr>
<tr>
<td>immune</td>
<td>10</td>
</tr>
<tr>
<td>genome</td>
<td>9</td>
</tr>
<tr>
<td>cancer</td>
<td>9</td>
</tr>
<tr>
<td>tumor</td>
<td>7</td>
</tr>
<tr>
<td>resistance</td>
<td>7</td>
</tr>
<tr>
<td>transcriptome</td>
<td>6</td>
</tr>
<tr>
<td>immunity</td>
<td>6</td>
</tr>
<tr>
<td>sequencing</td>
<td>5</td>
</tr>
<tr>
<td>T cell</td>
<td>5</td>
</tr>
<tr>
<td>leukemia</td>
<td>5</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>4</td>
</tr>
<tr>
<td>epigenetic</td>
<td>4</td>
</tr>
<tr>
<td>transcriptomics</td>
<td>4</td>
</tr>
<tr>
<td>metabolic</td>
<td>3</td>
</tr>
<tr>
<td>pathway</td>
<td>3</td>
</tr>
<tr>
<td>single-cell</td>
<td>3</td>
</tr>
<tr>
<td>aging</td>
<td>2</td>
</tr>
<tr>
<td>monocyte</td>
<td>2</td>
</tr>
<tr>
<td>histone</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (64æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302731" target="_blank" rel="noopener noreferrer">GSE302731 å®¶è¢‹ç‹¸ä¸‰å±‚è„ä¾§è†œçš„å¾®é‡RNAæµ‹åºç ”ç©¶èƒç›˜ç»†èƒå› å­ä¿¡å·ä¼ å¯¼</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE318164" target="_blank" rel="noopener noreferrer">GSE318164 åˆ†å­å¼‚è´¨æ€§å’Œå…ç–«æµ¸æ¶¦é©±åŠ¨ä¸Šå°¿è·¯å°¿è·¯ä¸Šçš®ç™Œçš„ä¸´åºŠç»“å±€</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317599" target="_blank" rel="noopener noreferrer">GSE317599 æŠ‘åˆ¶NEDDylationå¯é€šè¿‡çº¿ç²’ä½“è‡ªå™¬å»¶é•¿å¯¿å‘½å¹¶åœ¨è¡°è€è¿‡ç¨‹ä¸­ç»´æŒå¿ƒè„åŠŸèƒ½</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316764" target="_blank" rel="noopener noreferrer">GSE316764 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316618" target="_blank" rel="noopener noreferrer">GSE316618 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [Visium]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316616" target="_blank" rel="noopener noreferrer">GSE316616 ç»“è‚ ç‚å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE314758" target="_blank" rel="noopener noreferrer">GSE314758 åŒæ—¶æµ‹é‡ç¿»è¯‘é€Ÿç‡å’Œè½¬å½•ç»„æ­ç¤ºäº†æ´»è·ƒç»†èŒç»†èƒç¾¤ä½“å†…çš„å…³è”è°ƒæ§ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313713" target="_blank" rel="noopener noreferrer">GSE313713 NSD2 é€šè¿‡ Hippo ä¿¡å·é€šè·¯çš„è¡¨è§‚é—ä¼ è°ƒæ§é©±åŠ¨ç³–å°¿ç—…è‚¾ç—…ä¸­çš„è¶³ç»†èƒæŸä¼¤ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313573" target="_blank" rel="noopener noreferrer">GSE313573 å˜å½¢è™«æ ·é—´è´¨è½¬åŒ–å’Œç™Œç—‡ä¾µè¢­å¯å¡‘æ€§çš„è›‹ç™½æ°´è§£æ§åˆ¶ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE313572" target="_blank" rel="noopener noreferrer">GSE313572 å˜å½¢è™«æ ·é—´è´¨è½¬åŒ–å’Œç™Œç—‡ä¾µè¢­å¯å¡‘æ€§çš„è›‹ç™½æ°´è§£æ§åˆ¶ [scRNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308747" target="_blank" rel="noopener noreferrer">GSE308747 TCR-SUB1-DOCK2 ä¿¡å·è½´é€šè¿‡è°ƒèŠ‚ CD4+ T ç»†èƒè¿ç§»èƒ½åŠ›æ¥æ§åˆ¶è‡ªèº«å…ç–« [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE308746" target="_blank" rel="noopener noreferrer">GSE308746 TCR-SUB1-DOCK2 ä¿¡å·è½´é€šè¿‡è°ƒèŠ‚ CD4+ T ç»†èƒè¿ç§»èƒ½åŠ›æ¥æ§åˆ¶è‡ªèº«å…ç–« [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305438" target="_blank" rel="noopener noreferrer">GSE305438 NUDT21 åœ¨æ€¥æ€§ T æ·‹å·´ç»†èƒç™½è¡€ç—…ä¸­çš„ä½œç”¨æœºåˆ¶ç ”ç©¶ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE302132" target="_blank" rel="noopener noreferrer">GSE302132 å•ç»†èƒè½¬å½•ç»„å­¦æ­ç¤ºå°é¼ å•æ¬¡è‡­æ°§æš´éœ²æ¨¡å‹ä¸­è‚ºæ³¡å·¨å™¬ç»†èƒçš„ç‰¹å¼‚æ€§ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290624" target="_blank" rel="noopener noreferrer">GSE290624 é€šåºœå¹³å·æ±¤æ²»ç–—æˆ–ä¸æ²»ç–—è´¥è¡€ç—‡å¤§é¼ ç›²è‚ ç»„ç»‡çš„è½¬å½•ç»„æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE290518" target="_blank" rel="noopener noreferrer">GSE290518 é¶å‘METé…ªæ°¨é…¸æ¿€é…¶å’ŒNRF2ä¹‹é—´æ–°å‹ç›¸äº’ä½œç”¨å¯å¢å¼ºä¸‰é˜´æ€§ä¹³è…ºç™Œå¯¹ç´«æ‰é†‡çš„æ•æ„Ÿæ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289009" target="_blank" rel="noopener noreferrer">GSE289009 ç²’ç»†èƒæ¥æºçš„æŠµæŠ—ç´ è¯±å¯¼CMMLä¸­ç»å…¸å•æ ¸ç»†èƒé‡æ–°åˆ†å¸ƒå’Œå…ç–«æŠ‘åˆ¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288741" target="_blank" rel="noopener noreferrer">GSE288741 é€šè¿‡ CRISPR/Cas9 åŸºå› ç¼–è¾‘æŠ€æœ¯è¿ç»­æ•²å…¥è¡¨çš®ç”Ÿé•¿å› å­å—ä½“é…ä½“ç»“åˆåŸŸï¼Œå¯æ”¹å˜å…¶åœ¨å®«é¢ˆç™Œç»†èƒä¸­çš„äºšç»†èƒå®šä½å’Œç£·é…¸åŒ–æ°´å¹³ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288679" target="_blank" rel="noopener noreferrer">GSE288679 RNase H1 ä¾èµ–æ€§ R ç¯æ¸…é™¤æ˜¯å°é¼ åµå­å‘ç”Ÿè¿‡ç¨‹ä¸­åŸºå› ç»„æ²‰é»˜çš„å…ˆå†³æ¡ä»¶ [RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287246" target="_blank" rel="noopener noreferrer">GSE287246 å¹²æ‰°Tç»†èƒè®°å¿†å¯æ”¹å–„ä½“é‡æ³¢åŠ¨å¼•èµ·çš„è¿‡åº¦ä»£è°¢ååº”</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE287025" target="_blank" rel="noopener noreferrer">GSE287025 BCAAä»£è°¢é€šè¿‡èƒ†å›ºé†‡åˆæˆä¿®é¥°ä¿ƒè¿›è‚ºç™Œçš„è‚¿ç˜¤å‘ç”Ÿ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275500" target="_blank" rel="noopener noreferrer">GSE275500 TEX ç»†èƒå‘½è¿å’Œåˆ†åŒ–å— 3D åŸºå› ç»„é‡ç»„å’ŒæŸ“è‰²è´¨ç»“æ„å®Œæ•´æ€§çš„å½±å“ [Hi-C]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275499" target="_blank" rel="noopener noreferrer">GSE275499 TEX ç»†èƒå‘½è¿å’Œåˆ†åŒ–å— 3D åŸºå› ç»„é‡ç»„å’ŒæŸ“è‰²è´¨ç»“æ„å®Œæ•´æ€§çš„å½±å“ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275497" target="_blank" rel="noopener noreferrer">GSE275497 TEX ç»†èƒå‘½è¿å’Œåˆ†åŒ–å— 3D åŸºå› ç»„é‡ç»„å’ŒæŸ“è‰²è´¨ç»“æ„å®Œæ•´æ€§çš„å½±å“ [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE270215" target="_blank" rel="noopener noreferrer">GSE270215ï¼šè´åˆ©æœ¨å•æŠ—æ²»ç–—ç³»ç»Ÿæ€§çº¢æ–‘ç‹¼ç–®æ‚£è€…è¡€æ¶²å¤–å‘¨è¡€å•æ ¸ç»†èƒåŸºå› è¡¨è¾¾çš„å•ç»†èƒè½¬å½•ç»„æµ‹åºåˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE263903" target="_blank" rel="noopener noreferrer">GSE263903 å•ç»†èƒè½¬å½•ç»„å­¦ç ”ç©¶å‘ç°ï¼Œæš´éœ²äºçƒŸè‰å‘³ç”µå­çƒŸçš„å°é¼ è‚ºéƒ¨ä¸­æ€§ç²’ç»†èƒåŠ¨åŠ›å­¦å‘ç”Ÿæ”¹å˜ï¼ŒTç»†èƒç»†èƒæ¯’æ€§å¢å¼ºã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255094" target="_blank" rel="noopener noreferrer">GSE255094 PRC2 å¯åŠ¨äºŒä»·é¶åŸºå› çš„è½¬å½•è¯±å¯¼ï¼Œä¸”ä¸ä¾èµ–äºç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶æ´»æ€§ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE255093" target="_blank" rel="noopener noreferrer">GSE255093 PRC2 å¯åŠ¨äºŒä»·é¶åŸºå› çš„è½¬å½•è¯±å¯¼ï¼Œä¸”ä¸ä¾èµ–äºç»„è›‹ç™½ç”²åŸºè½¬ç§»é…¶æ´»æ€§ [ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225634" target="_blank" rel="noopener noreferrer">GSE225634 æ¥è‡ª M2 å·¨å™¬ç»†èƒæ¥æºçš„å¤–æ³Œä½“å¤„ç†çš„ MDA-MB-231 ä¹³è…ºç™Œç»†èƒçš„è¡¨è¾¾æ•°æ®</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE274080" target="_blank" rel="noopener noreferrer">GSE274080 RORÎ³t+ APC éœ€è¦ç‹¬ç‰¹çš„é¡ºå¼è°ƒæ§å…ƒä»¶æ¥æŒ‡å¯¼å¯¹è†³é£ŸæŠ—åŸçš„è€å—æ€§ [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317817" target="_blank" rel="noopener noreferrer">GSE317817 å¤šå·´èƒºç¥ç»å…ƒç‰¹å¼‚æ€§ RNA æµ‹åºæ­ç¤ºè„‘å•¡è‚½é…¶ 1 åœ¨é»è¿è›‹ç™½å¤åˆç‰©ä¸‹æ¸¸å‘æŒ¥ä½œç”¨ï¼ŒæŠ‘åˆ¶å­¦ä¹ </a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317753" target="_blank" rel="noopener noreferrer">GSE317753 æ‰è±†ï¼ˆLens culinaris Medik.ï¼‰ä¸­microRNAçš„å…¨åŸºå› ç»„é‰´å®šå’Œç»„ç»‡ç‰¹å¼‚æ€§åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE317276" target="_blank" rel="noopener noreferrer">GSE317276 æ•´åˆå¤šå¹³å°ä»£è°¢ç»„å­¦æ­ç¤ºèƒ«å‰é»æ¶²æ€§æ°´è‚¿ä¸­è„‚è‚ªé…¸ä»‹å¯¼çš„ç‚ç—‡ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316763" target="_blank" rel="noopener noreferrer">GSE316763 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [IVFP]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316762" target="_blank" rel="noopener noreferrer">GSE316762 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿[ç»„ç»‡ EM-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316761" target="_blank" rel="noopener noreferrer">GSE316761 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿[ç±»å™¨å®˜ EM-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316724" target="_blank" rel="noopener noreferrer">GSE316724 CHD2 çš„æ·±åº¦çªå˜æ‰«æï¼Œç”¨äºç¥ç»å‘è‚²éšœç¢çš„å˜å¼‚è§£è¯» [RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316617" target="_blank" rel="noopener noreferrer">GSE316617 ç»“è‚ ç‚çš„å…‹éš†è®°å¿†ç§¯ç´¯å¹¶ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ [CUT&amp;Tag]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316581" target="_blank" rel="noopener noreferrer">GSE316581 HOXB2æ•²ä½åMCF-7ä¹³è…ºç™Œç»†èƒçš„è½¬å½•ç»„åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE316113" target="_blank" rel="noopener noreferrer">GSE316113 Ly6C+Sca-1+è™šæ‹Ÿè®°å¿†CD8+ Tç»†èƒå“åº”IL-15/RÎ±å¤åˆç‰©ä¿ƒè¿›æ…¢æ€§è‚è„ç‚ç—‡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE315645" target="_blank" rel="noopener noreferrer">GSE315645 ç™½ç»†èƒä»‹ç´ -4:STAT6ä¿¡å·é€šè·¯é€šè¿‡æ‹®æŠ—IL-18æ„ŸçŸ¥å»¶è¿Ÿä¿æŠ¤æ€§CD8 Tç»†èƒçš„æ—è§‚è€…æ¿€æ´»</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311118" target="_blank" rel="noopener noreferrer">GSE311118 NSD2 é€šè¿‡ Hippo ä¿¡å·é€šè·¯çš„è¡¨è§‚é—ä¼ è°ƒæ§é©±åŠ¨ç³–å°¿ç—…è‚¾ç—…ä¸­çš„è¶³ç»†èƒæŸä¼¤ [Cut &amp; Run]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE311115" target="_blank" rel="noopener noreferrer">GSE311115 NSD2é€šè¿‡è¡¨è§‚é—ä¼ è°ƒæ§Hippoä¿¡å·é€šè·¯é©±åŠ¨ç³–å°¿ç—…è‚¾ç—…ä¸­çš„è¶³ç»†èƒæŸä¼¤</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310466" target="_blank" rel="noopener noreferrer">GSE310466 è¡¨è§‚é—ä¼ æŒç»­æ—¶é—´çš„ç§å†…å˜å¼‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310074" target="_blank" rel="noopener noreferrer">GSE310074 Î”Np73 äºšå‹å®šä¹‰äº†æ€¥æ€§é«“ç³»ç™½è¡€ç—…ä¸­ä¸€ç§ç±»ä¼¼ TP53 çªå˜çš„é¢„åä¸è‰¯äºšç»„ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310000" target="_blank" rel="noopener noreferrer">GSE310000 äººç±»èƒŒæ ¹ç¥ç»èŠ‚çš„ snRNA æµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309052" target="_blank" rel="noopener noreferrer">GSE309052 TCR-SUB1-DOCK2ä¿¡å·è½´é€šè¿‡è°ƒèŠ‚CD4+ Tç»†èƒè¿ç§»èƒ½åŠ›æ¥è°ƒæ§è‡ªèº«å…ç–«</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307402" target="_blank" rel="noopener noreferrer">GSE307402 ADAR1æ²‰é»˜å¯¹äººå•æ ¸ç»†èƒæ¥æºå·¨å™¬ç»†èƒçš„å½±å“</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE307015" target="_blank" rel="noopener noreferrer">GSE307015 é›„æ€§é‡ç”Ÿå‹å’ŒIRF8æ•²é™¤å‹å°èƒ¶è´¨ç»†èƒçš„è½¬å½•ç»„è°±</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305852" target="_blank" rel="noopener noreferrer">GSE305852 NUDT21 åœ¨æ€¥æ€§ T æ·‹å·´ç»†èƒç™½è¡€ç—…ä¸­çš„ä½œç”¨æœºåˆ¶ç ”ç©¶ [CUT&amp;Tag]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305851" target="_blank" rel="noopener noreferrer">GSE305851 NUDT21 åœ¨æ€¥æ€§ T æ·‹å·´ç»†èƒç™½è¡€ç—…ä¸­çš„ä½œç”¨æœºåˆ¶ç ”ç©¶ [eCLIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305770" target="_blank" rel="noopener noreferrer">GSE305770 å…¨è½¬å½•ç»„åˆ†ææ­ç¤ºäº†æ‚£æœ‰ç–¼ç—›æ€§ç³–å°¿ç—…å‘¨å›´ç¥ç»ç—…å˜çš„å¤§é¼ èƒŒæ ¹ç¥ç»èŠ‚çš„å…³é”®è°ƒæ§ç½‘ç»œå’Œæ½œåœ¨æ²»ç–—é¶ç‚¹</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305544" target="_blank" rel="noopener noreferrer">GSE305544 åŸºåº•å°¿è·¯ä¸Šçš®ç»†èƒä½œä¸ºè†€èƒ±ç™Œèµ·æºç»†èƒï¼Œå…¶å†…åœ¨åˆ†åŒ–ä¸ºä¸­é—´ç»†èƒå’Œä¼çŠ¶ç»†èƒçš„èƒ½åŠ›æ›´å¼º</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305440" target="_blank" rel="noopener noreferrer">GSE305440 NUDT21 åœ¨æ€¥æ€§ T æ·‹å·´ç»†èƒç™½è¡€ç—…ä¸­çš„ä½œç”¨æœºåˆ¶ç ”ç©¶ [PAS-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE289271" target="_blank" rel="noopener noreferrer">GSE289271 è¡°è€ç›¸å…³çš„UFMylationè°ƒæ§é˜»ç¢ç§€ä¸½éšæ†çº¿è™«çš„è›‹ç™½è´¨ç¨³æ€</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288680" target="_blank" rel="noopener noreferrer">GSE288680 RNase H1 ä¾èµ–æ€§ R ç¯æ¸…é™¤æ˜¯å°é¼ åµå­å‘ç”Ÿè¿‡ç¨‹ä¸­åŸºå› ç»„æ²‰é»˜çš„å…ˆå†³æ¡ä»¶ [Stacc-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE288634" target="_blank" rel="noopener noreferrer">GSE288634 RNase H1ä¾èµ–çš„Rç¯æ¸…é™¤æ˜¯å°é¼ åµå­å‘ç”Ÿè¿‡ç¨‹ä¸­åŸºå› ç»„æ²‰é»˜çš„å…ˆå†³æ¡ä»¶</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE286918" target="_blank" rel="noopener noreferrer">GSE286918 åµå·¢å‚¨å¤‡åŠŸèƒ½å‡é€€æ‚£è€…é¢—ç²’ç»†èƒä¸­å‘ç”Ÿçš„ä»£è°¢é‡ç¼–ç¨‹å’Œé“æ­»äº¡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE275498" target="_blank" rel="noopener noreferrer">GSE275498 TEX ç»†èƒå‘½è¿å’Œåˆ†åŒ–å— 3D åŸºå› ç»„é‡ç»„å’ŒæŸ“è‰²è´¨ç»“æ„å®Œæ•´æ€§çš„å½±å“ [CUT&amp;RUN]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE259315" target="_blank" rel="noopener noreferrer">GSE259315 èœ‚ç‹æµ†é…¸åœ¨æºƒç–¡æ€§ç»“è‚ ç‚æ²»ç–—ä¸­çš„åº”ç”¨ï¼šé€šè¿‡ miRNA è¡¨è¾¾å’Œ NLRP3 ç‚ç—‡å°ä½“è°ƒèŠ‚ miR-210-3P/Gbp3 é€šè·¯å’Œç»†èƒç„¦äº¡ï¼ˆmiRNA-Seqï¼‰</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE256425" target="_blank" rel="noopener noreferrer">GSE256425 èœ‚ç‹æµ†é…¸åœ¨æºƒç–¡æ€§ç»“è‚ ç‚æ²»ç–—ä¸­çš„åº”ç”¨ï¼šé€šè¿‡ miRNA è¡¨è¾¾å’Œ NLRP3 ç‚ç—‡å°ä½“è°ƒèŠ‚ miR-210-3P/Gbp3 é€šè·¯å’Œç»†èƒç„¦äº¡</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE246725" target="_blank" rel="noopener noreferrer">GSE246725 TPX2 ä½œä¸º MYCN é©±åŠ¨çš„ç¥ç»æ¯ç»†èƒç˜¤ä¸­ eIF4A æ§åˆ¶çš„ç¿»è¯‘ç¨‹åºçš„å…³é”®ä¸‹æ¸¸é¶ç‚¹[RNA-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE225870" target="_blank" rel="noopener noreferrer">GSE225870 åŸºäºè½¬å½•ç»„å­¦çš„æˆå¹´æ–‘é©¬é±¼ï¼ˆDanio rerioï¼‰é•¿æœŸæš´éœ²äºåŒé…šAFåè‚æ¯’æ€§æ€§åˆ«å·®å¼‚æœºåˆ¶åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE117956" target="_blank" rel="noopener noreferrer">GSE117956 ç¥ç»è§†ç½‘è†œçš„ç»†èƒç¯å¢ƒå½±å“è¡¥ä½“å…ç–«è°ƒèŠ‚ [Hs]</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2026-02-01 21:42</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>